Tissue Engineered Veins in Patients With Chronic Venous Insufficiency

Launched by VERIGRAFT AB · Dec 20, 2018

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for patients with chronic venous insufficiency (CVI), a condition where the veins in the legs struggle to return blood to the heart, leading to pain and swelling. The study aims to assess the safety of personalized tissue-engineered veins (P-TEVs) that are designed to replace damaged sections of the femoral vein. Each P-TEV includes a functioning valve, which may help improve blood flow and reduce symptoms for patients suffering from severe CVI.

To participate in this trial, individuals must be between 18 and 75 years old and have experienced painful swelling or skin changes in their legs despite receiving the best standard treatment. They should also have a specific type of vein problem called deep venous reflux. Participants will undergo surgery to have their damaged vein replaced with the engineered vein. Throughout the study, researchers will monitor for any side effects or complications. If you're considering joining, it's essential to discuss with your doctor to see if you meet the eligibility criteria and to understand what the study involves.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged between 18 and 75 years (inclusive)
• • CVI patients with painful swelling and/or skin changes and/or recurrent leg ulcer despite optimal conservative treatment for a period of time according to the investigator's judgement
• • Patients with deep venous reflux (grade 3 and above)
• • Meeting ASA (American Society of Anesthesiologists Classification) class 1 or 2 according to the PIs criteria
• • Laboratory values
• • INR \<1.7 (in case the patient uses Warfarin, the test might be repeated after the anticoagulant change)
• • Platelets ≥ 100 x 10 9 /L
• • Hemoglobin ≥ 100 g/L
• • Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
• • ASAT ≤ 2.5 × ULN
• • ALAT ≤ 2.5 × ULN
• • Ability to understand the requirements of the study, give direct or representative written informed consent, and comply with the study procedures
• Exclusion Criteria:
• • Patients incapable to give direct or representative written informed consent
• • Patients unlikely to cooperate fully in the study and/or with an anticipated poor compliance
• • Non-walking patients or patients with lost ankle joint function
• • Patients previously organ-transplanted
• • Patients with cancer except in-situ stage cancer (basal-cell carcinomas and/or cervix cancer) and five year recurrence free period after treatment
• • Patients with autoimmune diseases including rheumatoid arthritis, SLE and MS
• • Pregnant or breast feeding women
• • Patients with ongoing estrogen treatment for example for contraception. Alternative contraceptive methods (e.g. intrauterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence) should be used by women of reproductive age (defined as pre-menopausal female capable of becoming pregnant).
• • BMI ≥ 35
• • Patients who have participated in other clinical trials during the last 12 months
• • Patients with artery pathology (ankle-brachial pressure index \< 0,9 or \> 1,3)
• • Patients with thrombophilia according to the laboratory results at inclusion visit. One of the following criteria is needed for thrombophilia: Protein C \< 40% or Protein S \< 40 % or Leiden factor mutation or Antithrombin III \< 40 % or present Lupus anticoagulant or Homocysteine \> 1.5 ULN
• • Patients with an active infection requiring systemic antibiotic treatment
• • Patients with clinically significant cardiac disease (New York Heart Association, Class III or IV) or measured LVEF 40%
• • Patients with uncontrolled hypertension
• • Patients with renal dysfunction eGFR \< 45 ml/min (according to the MDRD calculation)
• • Patients with moderate or severe hepatic impairment (Child Pugh ≥ 7 points, i.e. class B or C)
• • Patients with ongoing immunosuppression, systemic Cortisol treatment etc.
• • Less than 3 months since previous ipsilateral venous intervention (e.g. Iliac recanalization)
• • Clinically significant iliocaval stenosis or occlusion
• • Current smoker of more than 20 cigarettes per day
• • Other uncontrolled intercurrent illness that would jeopardize the patient's safety, interfere with the objectives of the protocol, or limit the patient's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor
• • Patients with severe SARSCoV-2 virus infection requiring hospitalization in the past 6 months